Abstract
Clinically Isolated Syndrome (CIS), denotes the first neurological symptom suggestive of Multiple Sclerosis (MS), at least 24 hours in duration; In the absence of fever, infectious processes and encephalopathy. It is characterized by its frequent presentation in young adults and affects the optic nerve, brainstem or spinal cord. The early stratification of CIS is essential because with clinical, radiological and biological predictors, the risk of conversion to MS can be established. The use of Disease Modifying Therapies (DMT) in CIS has been shown to delay the conversion of CIS to Multiple Sclerosis by 44 to 50 %%. However, not all patients with CIS will evolve to MS, so the study of several prognostic markers will allow to recognize the ideal scenario where patients benefit from the early onset of DMT.
References
Compston A, Coles A. Multiple sclerosis. Lancet. 2008;372:1502-17.
Miller DH, Chard DT, Ciccarelli O. Clinically isolated syndromes. Lancet Neurol. 2012;11(2):157-69.
Miller D, Barkhof F, Montalban X, Thompson A, Filippi M. Clinically isolated syndromes suggestive of multiple sclerosis, part I: Natural history, pathogenesis, diagnosis, and prognosis. Lancet Neurol. 2005; 4:281-8.
Confavreux C, Vukusic S, Adeleine P. Early clinical predictors and progression of irreversible disability in multiple sclerosis: An amnesic process. Brain. 2003;126(4):770-82.
Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, et al. Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria. Ann Neurol. 2011;69(2):292-302.
Compston A, Confavreux C, Lassmann H, McDonald I, Miller D, Noseworthy J, et al. Treatment of the acute relapse. En: McAlpine's multiple sclerosis. 2006. p .683-699. Disponible en: http://www.sciencedirect.com/science/article/pii/B9780443072710500185
Dalton CM, Bodini B, Samson RS, Battaglini M, Fisniku LK, Thompson AJ, et al. Brain lesion location and clinical status 20 years after a diagnosis of clinically isolated syndrome suggestive of multiple sclerosis. Mult Scler. 2012 [citado 2014 agosto 22];18(3):322-8. Disponible en: Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/21878451
Okuda DT, Mowry EM, Beheshtian A, Waubant E, Baranzini SE, Goodin DS, et al. Incidental MRI anomalies suggestive of multiple sclerosis: The radiologically isolated syndrome. Neurology. 2009;72(9):800-5.
Keltner JL, Johnson CA, Spurr JO, Beck RW. Baseline visual field profile of optic neuritis. The experience of the optic neuritis treatment trial. Optic Neuritis Study Group. Arch Ophthalmol. 1993;111(2):231-4.
Hickman S, Dalton C, Miller D, Plant G. Management of acute optic neuritis. Lancet. 2002;360(9349):1953-62.
Toosy AT, Mason DF, Miller DH. Optic neuritis. Lancet Neurol. 2014;13:83-99.
de Seze J, Stojkovic T, Breteau G, Lucas C, Michon-Pasturel U, Gauvrit JY, et al. Acute myelopathies: Clinical, laboratory and outcome profiles in 79 cases. Brain. 2001;124(Pt 8):1509-21.
Awad A, Hemmer B, Hartung HP, Kieseier B, Bennett JL, Stuve O. Analyses of cerebrospinal fluid in the diagnosis and monitoring of multiple sclerosis. J Neuroimmunol. 2010 [citado 2014 ago. 6];219(1-2):1-7. Disponible en: Disponible en: http://wwwncbi.nlm.nih.gov/pubmed/19782408
Cruccu G, Aminoff MJ, Curio G, Guerit JM, Kakigi R, Mauguiere F, et al. Recommendations for the clinical use of somatosensory-evoked potentials. Clin Neurophysiol.. 2008;119:1705-19.
Rovira A, León A. MR in the diagnosis and monitoring of multiple sclerosis: An overview. Eur J Radiol. 2008;67(3):409-14.
Tintoré M, Rovira A, Río J, Nos C, Grivé E, Téllez N, et al. Baseline MRI predicts future attacks and disability in clinically isolated syndromes. Neurology. 2006;67(6):968-72. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/17000962
Optic Neuritis Study Group TONS. Multiple sclerosis risk after optic neuritis: final optic neuritis treatment trial follow-up. Arch Neurol. 2008;65(6):727-32.
Kuhle J, Disanto G, Dobson R, Adiutori R, Bianchi L, Topping J, et al. Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study. Mult Scler J. 2015;21(8):1013-24.
Tintore M, Rovira A, Arrambide G, Mitjana R, Río J, Auger C, et al. Brainstem lesions in clinically isolated syndromes. Neurology. 2010;75(21):1933-8.
Odenthal C, Coulthard A. The prognostic utility of MRI in clinically isolated syndrome: A literature review. Am J Neuroradiol. 2014;36(3):425-31.
Bakshi R, Minagar A, Jaisani Z, Wolinsky JS. Imaging of multiple sclerosis: role in neurotherapeutics. NeuroRx. 2005;2(2):277-303.
Cordonnier C, de Seze J, Breteau G, Ferriby D, Michelin E, Stojkovic T, et al. Prospective study of patients presenting with acute partial transverse myelopathy. J Neurol. 2003;250(12):1447-52.
Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2017;17(2):162-73.
Calabrese M, Rinaldi F, Mattisi I, Bernardi V, Favaretto A, Perini P, et al. The predictive value of gray matter atrophy in clinically isolated syndromes. Neurology. 2011;77(3):257-63.
Traboulsee A, Simon JH, Stone L, Fisher E, Jones DE, Mal-hotra A, et al. Revised recommendations of the consortium of MS centers task force for a standardized MRI protocol and clinical guidelines for the diagnosis and follow-up of multiple sclerosis. Am J Neuroradiol. 2016; 37(3):394-401.
Filippi M, Rocca MA, Ciccarelli O, De Stefano N, Evangelou N, Kappos L, et al. MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines. Lancet Neurol. 2016; 15(3):292-303.
Wagner J, Williams S, Webster CJ. Biomarkers and surrogate end points for fit-for-purpose development and regulatory evaluation of new drugs. Clin Pharmacol Ther. 2007;81(1):104-7.
Fitzner B, Hecker M, Zettl UK. Molecular biomarkers in cerebrospinal fluid of multiple sclerosis patients. Autoimmun Rev. 2015;14:903-13.
Freedman MS, Thompson EJ, Deisenhammer F, Giovannoni G, Grimsley G, Keir G, et al. Recommended standard of cerebrospinal fluid analysis in the diagnosis of multiple sclerosis: a consensus statement. Arch Neurol. 2005;62(6):865-70.
Masjuan J, Alvarez-Cermeño JC, García-Barragán N, Díaz-Sánchez M, Espiño M, Sádaba MC, et al. Clinically isolated syndromes: A new oligoclonal band test accurately predicts conversion to MS. Neurology. 2006;66(4):576-8.
Tintoré M, Rovira A, Río J, Tur C, Pelayo R, Nos C, et al. Do oligoclonal bands add information to MRI in first attacks of multiple sclerosis? Neurology. 2008;70(13 Pt 2):1079-83.
Comabella M, Fernández M, Martin R, Rivera-Vallvé S, Borrás E, Chiva C, et al. Cerebrospinal fluid chitinase 3-like 1 levels are associated with conversion to multiple sclerosis. Brain. 2010;133(4):1082-93.
Teunissen CE, Iacobaeus E, Khademi M, Brundin L, Norgren N, Koel-Simmelink MJA, et al. Combination of CSF N-acetylaspartate and neurofilaments in multiple sclerosis. Neurology. 2009;72(15):1322-9.
Norgren N, Sundstrom P, Svenningsson A, Rosengren L, Stigbrand T, Gunnarsson M. Neurofilament and glial fibrillary acidic protein in multiple sclerosis. Neurology. 2004;63(9):1586-90.
Mowry EM, Pesic M, Grimes B, Deen SR, Bacchetti P, Waubant E. Clinical predictors of early second event in patients with clinically isolated syndrome. J Neurol. 2009 [citado 2014 ago. 8];256(7):1061-6. Disponible en: Disponible en: http://www.pubmedcentr.al. nih.gov/articlerender.fcgi?artid=2708331&tool=pmcentrez& rendertype=abstract
Dobson R, Ramagopalan S, Giovannoni G. The effect of gender in clinically isolated syndrome (CIS): a meta-analysis. Mult Scler. 2012 [citado 2014 ago 8];18(5):600-4. Disponible en: Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/21993498
Polman C, Kappos L, Freedman MS, Edan G, Hartung HP, Miller DH, et al. Subgroups of the BENEFIT study: Risk of developing MS and treatment effect of interferon beta-1b. J Neurol. 2008;255(4):480-7.
Jacobs LD, Beck RW, Simon JH, Kinkel RP, Brownscheidle CM, Murray TJ, et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med. 2000;343(13):898-904.
Dobson R, Giovannoni G, Ramagopalan S. The month of birth effect in multiple sclerosis: systematic review, meta-analysis and effect of latitude. J Neurol Neurosurg Psychiatry. 2012;84(4):472-83.
Wing AC, Vasconcelos CCF, Calvet J, Papais-Alvarenga RM, Thuler LCS. Risk factors for convertion to clinically defined multiple sclerosis after clinically isolated syndrome in a racially mixed Brazilian cohort. Clin Neurol Neurosurg. 2016;146:40-4.
Sand IK. Classification, diagnosis, and differential diagnosis of multiple sclerosis. Curr Opin Neurol. 2015;28(3):193-205.
Shimizu J, Hatanaka Y, Hasegawa M, Iwata A, Sugimoto I, Date H, et al. IFN??-1b may severely exacerbate Japanese optic-spinal MS in neuromyelitis optica spectrum. Neurology. 2010;75(16):1423-7.
Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG. The spectrum of neuromyelitis optica. Lancet Neurol. 2007;6:805-15.
Wingerchuk DM, Weinshenker BG. Neuromyelitis optica: clinical predictors of a relapsing course and survival. Neurology. 2003;60(5):848-53.
Jarius S, Paul F, Franciotta D, Ruprecht K, Ringelstein M, Bergamaschi R, et al. Cerebrospinal fluid findings in aqua-porin-4 antibody positive neuromyelitis optica: results from 211 lumbar punctures. J Neurol Sci. 2011 [citado 2014 ago. 22];306(1-2):82-90. Disponible en: Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/21550068
Hyun JW, Jeong IH, Joung A, Kim S-H, Kim HJ. Evaluation of the 2015 diagnostic criteria for neuromyelitis optica spectrum disorder. Neurology. 2016;86(19):1772-9.
Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W Chitnis T, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015;85(2):177-89.
Tenembaum S, Chamoles N, Fejerman N. Acute disseminated encephalomyelitis: a long-term follow-up study of 84 pediatric patients. Neurology. 2002;59(8):1224-31.
Pohl D, Alper G, Van Haren K, Kornberg AJ, Lucchinetti CF, Tenembaum S, et al. Acute disseminated encephalomyelitis: Updates on an inflammatory CNS syndrome. Neurology. 2016;87(9):S38-45.
Kamate M, Chetal V, Tonape V, Mahantshetti N, Hattiholi V Central nervous system inflammatory demyelinating disorders of childhood. Ann Indian Acad Neurol. 2010;13(4):289-92.
Comi G, Filippi M, Barkhof F, Durelli L, Edan G, Fernández O, et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: A randomised study. Lancet. 2001;357(9268):1576-82.
Beck RW, Cleary PA. Optic neuritis treatment trial. One-year follow-up results. Arch Ophthalmol. 1993;111(6):773-5.
Dovio A, Perazzolo L, Osella G, Ventura M, Termine A, Milano E, et al. Immediate fall of bone formation and transient increase of bone resorption in the course of high-dose, short-term glucocorticoid therapy in young patients with multiple sclerosis. J Clin Endocrinol Metab. 2004;89(10):4923-8.
Lyons PR, Newman PK, Saunders M. Methylprednisolone therapy in multiple sclerosis: a profile of adverse effects. J Neurol Neurosurg Psychiatry. 1988;51:285-7.
Tintore M, Rovira A, Río J, Otero-Romero S, Arrambide G, Tur C, et al. Defining high, medium and low impact prognostic factors for developing multiple sclerosis. Brain. 2015;138(7):1863-74.
Kappos L, Polman CH, Freedman MS, Edan G, Hartung HP, Miller DH, et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology. 2006;67(7):1242-9.
Comi G, Martinelli V, Rodegher M, Moiola L, Bajenaru O, Carra A, et al. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. The Lancet. 2009;374(9700):1503-11.
Kinkel RP. IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event. Neurology. 2006;66(5):678-84.
Miller AE, Wolinsky JS, Kappos L, Comi G, Freedman MS, Olsson TP, et al. Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): A randomised, doubleblind, placebo-controlled, phase 3 trial. Lancet Neurol. 2014;13(10):977-86.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.